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are a dominant species in the study 
area and usually parasitize a variety 
of wild and domestic animals. These 
ticks often feed on humans as alterna-
tive hosts. Because this Roseomonas 
sp. is not a common pathogen, its role 
in public health and veterinary medi-
cine is unkown.
Phenotypic characterization of 
the isolates indicated similarities with 
previously reported Roseomonas spp. 
Phylogenetic analysis showed that the 
novel Roseomonas sp. is closely relat-
ed to R. cervicalis, which was isolated 
from a cancer patient. Our isolates also 
differed from 2 reported strains iso-
lated from freshwater lake sediment in 
Jiangsu Province, China (9) and from 
soil in Fujian Province, China (10). 
This result indicated the species diver-
sity of the genus Roseomonas, which 
might be related to different bacterial 
origins. Because of the unique bio-
chemical characteristics, antimicro-
bial drug susceptibilities, and novel 
isolation source of our isolates, the 
pathogenesis of this organism should 
be investigated.
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Misindentiﬁ  cation 
of Mycobacterium 
kumamotonense 
as M. tuberculosis 
To the Editor: Because of slow 
growth of mycobacteria, use of rapid 
tests to identify them is strongly rec-
ommended; rapid tests are widely 
used as an advanced diagnostic tool in 
clinical laboratories (1,2). These tests 
are particularly useful for diagnos-
ing extrapulmonary mycobacterioses 
and identifying unusual mycobacteria 
as etiologic agents (3). Commercial 
probes are frequently used for rapid 
and speciﬁ  c  identiﬁ   cation of myco-
bacteria, especially Mycobacterium 
tuberculosis complex. However, cross-
reactivity of DNA probes between 
mycobacterial species could result in 
incorrect diagnosis and treatment of 
patients (4,5). Misidentiﬁ  cation could 
be a problem if a newly described spe-
cies, such as M. kumamotonense (6), 
were an etiologic agent of a disease.
In July 2006, we obtained a ﬁ  ne-
needle, puncture aspiration biopsy 
specimen from a cervical lymph node 
of a 30-year-old man at Doce de Oc-
tubre Hospital (Madrid, Spain). The 
patient was a recent immigrant from 
Paraguay and was HIV positive (C2 
stage of infection). A biopsy speci-
men from a cervical lymph node 
showed necrotizing granulomatous 
lymphadenopathy. A computed to-
mographic scan showed cervico-tho-
raco-abdominal, multiple cervical, 
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supraclavicular, axillar, paratracheal, 
and mediastinal lymphadenopathies. 
The patient had a CD4 cell count of 
219 cells/mm3 and an HIV viral load 
of 197,181 copies/mL.
The aspiration sample was posi-
tive for acid-fast bacilli by ﬂ  uorescent 
staining. The clinical isolate (desig-
nated 1369) obtained from the aspi-
rate sample was grown in liquid media 
(MGIT Diagnostic Kit; Becton Dick-
inson Diagnostics, Sparks, MD, USA) 
and identiﬁ  ed as M. tuberculosis com-
plex by using the AccuProbe System 
(bioMérieux, Marcy l’Etoile, France).
A diagnosis of lymphoid tuber-
culosis was made, and the patient 
was treated with isoniazid, rifampin, 
ethambutol, and pyrazinamide. After 
1 month, rifampin was withdrawn be-
cause of a cutaneous exanthem. Three 
months later, the clinical status of the 
patient had improved, fever had dis-
appeared, and sizes of cervical and 
axillary lymph nodes had decreased. 
Treatment with tenofovir, emtricit-
abine, and lopinavir/ritonavir was 
started. Two weeks later, an immune 
reconstitution syndrome and adenopa-
thies developed, but these resolved in 
1 month.
Five months after treatment was 
started, susceptibility testing in a ref-
erence laboratory showed that isolate 
1369 was M.  kumamotonense. The 
isolate showed 100% identity with the 
16S rRNA gene sequence of M. kuma-
motonense (GenBank accession no. 
AB239925). Results of PCR restric-
tion analysis of heat shock protein 65 
gene (7) (http://app.chuv.ch/prasite/in-
dex.html) were consistent with those 
for  M.  kumamotonense. The isolate 
was susceptible to ethambutol, ri-
fampin, cycloserine, and ethionamide 
and resistant to isoniazid, streptomy-
cin, pyrazinamide, and kanamycin.
Because of the improvement in 
the clinical status of the patient, treat-
ment continued without modiﬁ  cation 
for 18 months. At this time, his CD4 
cell count was 488 cells/mm3 and his 
HIV viral load was <50 copies/mL. In 
July 2009, the patient was asymptom-
atic and had a CD4 cell count of 631 
cells/mm3 and an HIV viral load <50 
copies/mL.
To conﬁ  rm misidentiﬁ  cation of M. 
kumamotonense as a member of the M. 
tuberculosis complex, other commer-
cial probes were tested. Isolate 1369 
was also misidentiﬁ  ed as M. tubercu-
losis complex by Inno-LIPA v2 (In-
nogenetics, Ghent, Belgium). The iso-
late was identiﬁ  ed as Mycobacterium 
sp. by Geno-Type (Hain Lifescience, 
Nehren, Germany). The 3 commercial 
probes we used had different genome 
region speciﬁ  cities, all in the myco-
bacterial ribosomal operon. The Ac-
cuProbe System was speciﬁ  c for 16S 
rDNA, Inno-LIPA v2 was speciﬁ  c for 
internal transcribed spacer 1, and Ge-
no-Type was speciﬁ  c for 23S rDNA. 
Only Geno-Type did not show cross-
reactivity between M. tuberculosis 
complex and M. kumamotonense. The 
clinical isolate was identiﬁ  ed  as  M. 
kumamotonense, a new, slow-growing 
mycobacterium that was ﬁ  rst isolated 
from an immunocompetent patient in 
Japan (6). We showed that this species 
caused extrapulmonary disease in an 
HIV-positive patient.
Misidentiﬁ  cation of M. kumamo-
tonense as M. tuberculosis complex by 
commercial DNA probes has serious 
clinical implications. Once a patient 
is given a diagnosis of tuberculosis, 
he or she will be treated with speciﬁ  c 
drugs for a long period and be prone to 
adverse side effects. Furthermore, M. 
kumamotonense is resistant to many 
drugs used during typical treatment. 
After a diagnosis of tuberculosis, pa-
tient contacts need to be investigated 
to identify new cases. Emerging my-
cobacterial pathogens, such as M. ku-
mamotonense, may also cause pulmo-
nary and extrapulmonary infections 
that are also caused by other members 
of this genus and could be misidenti-
ﬁ  ed as M. tuberculosis.
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Mycobacterium 
conceptionense 
Infection after 
Breast Implant 
Surgery, France
To the Editor:  Mycobacterium 
fortuitum complex members are rap-
idly growing mycobacteria found in 
water and soil (1). These opportunistic 
pathogens are responsible for posttrau-
matic skin and soft tissue infections. 
They also account for 60%–80% of 
postsurgical wound infections caused 
by rapidly growing mycobacteria (2), 
particularly after breast surgery (with 
or without prosthetic implants) (3). M. 
conceptionense, an emerging member 
of the M. fortuitum complex, was ini-
tially described in a case of osteomy-
elitis that occurred after an open frac-
ture of the tibia (4). We report a case 
of  M. conceptionense infection that 
occurred after breast surgery.
A woman 58 years of age had a 
left mastectomy with lymph node dis-
section and chemotherapy for breast 
carcinoma in March 2004. Three years 
later, she underwent breast reconstruc-
tion that used a cutaneomuscular 
latissimus dorsi ﬂ  ap with a prosthetic 
implant. Immediately after surgery, a 
fever (39°C) developed, but 3 blood 
cultures remained sterile. No treat-
ment was administered, and she be-
came afebrile within 3 days.
At day 15 after surgery, a serous 
discharge appeared in the tip of the 
skin ﬂ  ap. By day 21, the patient was 
again febrile, and the wound discharge 
was swabbed for analysis. On day 27, 
she underwent surgical revision with 
ablation of the breast implant, drain-
age, and sample collection. The leuko-
cyte count was normal. However, the 
C-reactive protein level was 99 mg/L, 
and the erythrocyte sedimentation rate 
was 111 mm (ﬁ  rst hour). Treatment 
with intravenous amoxicillin/clavu-
lanic acid was started. Although the 
biologic parameters normalized, the 
serous discharge continued. Micro-
scopic examination of specimens from   
days 21 and 27 yielded no bacteria in 
Gram- and Ziehl-Nielsen–stained pus 
specimens, and standard bacteriologic 
cultures remained sterile. M. concep-
tionense, identiﬁ   ed by partial rpoB 
gene sequencing (100% identity with 
GenBank accession no. AY859695.1) 
(4), grew in both specimens after 8 
days of incubation at 37°C under a 5% 
CO2 atmosphere in Coletsos medium 
(bioMérieux, La Balme-les-Grottes, 
France). By the Etest method (4), both 
isolates were susceptible to several an-
timicrobial drugs, including clarithro-
mycin, amikacin, ciproﬂ  oxacin,  and 
doxycycline. The patient was treated 
with ciproﬂ  oxacin, azythromycin, and 
amikacin for 3 weeks, followed by 
ciproﬂ  oxacin and azythromycin for 4 
weeks.
At patient’s relapse 3 months 
later,  M. conceptionense exhibiting 
identical antimicrobial drug suscepti-
bility pattern was again isolated from 
the wound ﬂ  uid. The patient was then 
treated with ciproﬂ  oxacin,  azythro-
mycin, and doxycycline for 6 months; 
subsequently, doxycycline alone was 
given for a total of 18 months. Results 
from the 2-month follow-up examina-
tion were unremarkable.
M. conceptionense was unambig-
uously identiﬁ  ed by partial rpoB gene 
sequencing, a ﬁ  rst-line tool for accurate 
identiﬁ  cation of nontuberculous myco-
bacteria (5). A pathogenic role for M. 
conceptionense was supported by 1) 
its repetitive isolation from the wound; 
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Table. Three cases of Mycobacterium conceptionense infection in female patients* 
Patient
age, y  Clinical situation  Identification
Treatment 
Reference  Nature Duration, mo
31 Posttraumatic osteitis  16S rRNA, soda, hsp65,
recA, rpoB†
Antimicrobial drug therapy: AMC  3 (4)
43 Subcutaneous abscess 
without trauma 
partial 1,464-bp 16S rRNA 
gene‡ 
Surgery and antimicrobial drug  
therapy: COT and CLA; then DOX and 
CLA; then LIN and CLA 
5( 10)
58 Breast implant infection  rpoB§  Surgery and antimicrobial drug  
therapy: CIP and AZY; then CIP, AZY, 
and DOX; then DOX 
18 This report 
*AMC, amoxicillin/clavulanic acid; COT, cotrimoxazole; CLA, clarithromycin; DOX, doxycycline; LIN, linezolid; CIP, ciprofloxacin, AZY, azythromycin. The 
outcome for all 3 patients was favorable.  
†GenBank accession nos.: 16S rRNA, AY859684; rpoB, AY859695; hsp65, AY859678; sodA, AY859708; recA, AY859690. 
‡GenBank accession no. AM884289.1. 
§GenBank accession no. AY859695.1. 